Guenette 2011.

Methods	Design: cross‐over group Randomisation: yes, method not stated Blinding: double‐blind, placebo‐controlled Withdrawals: stated
Participants	Setting: hospital outpatient clinic Number eligible: not stated Number enrolled: 17 Number in groups: 17 (cross‐over) Number of withdrawals: 0 Number completing trial: 17 Age range: > 40 years old Sex: 12 M, 5 F Ethnicity: not stated (multicentre) COPD diagnosis: clinically stable COPD patients Severity of COPD: mean FEV1 54% predicted Inclusion criteria: > 40 years with a clinical diagnosis of COPD for at least 1 year, smoking > 20 pack‐years, FEV1 < 70% predicted, FEV1/FVC < 0.7, FRC > 120% predicted and moderate to severe chronic activity‐related dyspnoea as evidenced by a modified baseline Dyspnoea Index focal score < 6 Exclusion criteria: asthma, other condition leading to dyspnoea, hospitalised or lower respiratory tract infection 4 week prior, oxygen saturation < 80% during exercise Baseline characteristics of treatment/control groups: comparable
Interventions	FP 500 µg twice daily Placebo twice daily 2 weeks (with 2 weeks washout)
Outcomes	Borg dyspnoea score during exercise, cycle endurance, spirometry, lung volumes
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomised"
Allocation concealment (selection bias)	Unclear risk	Information not available
Blinding (performance bias and detection bias) All outcomes	Low risk	Quote: "double blind"
Incomplete outcome data (attrition bias) All outcomes	Low risk	No withdrawals
Selective reporting (reporting bias)	Low risk	All outcomes reported